



Clinical Edit Criteria Proposal

Drug/Drug Class: **Short Acting Opioids Clinical Edit**

Date: **March 6, 2018**

Prepared for:

Prepared by: **MO HealthNet**

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: Ensure safe, appropriate utilization and control of short-acting opioids.

Short-acting opioids (i.e. immediate- or regular-release oral morphine, hydromorphone, oxycodone, and codeine) are indicated for short-term relief of moderate to severe pain on an “as needed” basis. These medications are often used in conjunction with a long acting opioid to help relieve breakthrough pain. Although highly effective for pain control, these substances carry with them the potential for harm from adverse drug events and/or overdose. Opioid drugs also have substantial misuse liability and are often implicated among persons who have developed a substance misuse disorder. Concomitant use of benzodiazepines significantly increases the risk of harm from opioids.

Why was this Issue Selected:

In March 2016, the Centers for Disease Control and Prevention (CDC) released their Guideline for Prescribing Opioids for Chronic Pain. Although these guidelines focus on managing chronic pain, they emphasize the need for prescribers to be more judicious in the initiation and continuation, selection, and monitoring of opioids and other medications for acute pain. As part of the efforts to protect patients from the possible adverse effects of opioid medications and their subsequent diversion and misuse, MO HealthNet Division will continue to clinically edit the use of these controlled substances. Preventative activities include limiting prescription amounts and frequency of dispensing. Limiting or reducing “morphine-equivalent-doses” helps avoid harmful effects of opioids and promotes patient safety. Opioid daily doses above 50 Morphine-Milligram-Equivalents (50 MME/day) increase the risk of overdose by at least double.

MO HealthNet will continue to implement clinical edit criteria to help ensure safer opioid utilization for our MO HealthNet participants.

Setting & All patients

Population:

- Type of Criteria:** **Increased risk of ADE** **Non-Preferred Agent**
 Appropriate Indications **Other:**
- Data Sources:** **Only administrative databases** **Databases + Prescriber-supplied**
- Program-Specific Information:** **Short-Acting Opioid Analgesics - See Appendix A and Appendix B**

Setting & Population

- Age range: All patients
- Claims for patients under 18 years of age are subject to clinical review.
- Gender: males and females

Approval Criteria

Condition	Inferred Drugs	Date Range
Cancer	NA	2 years
	Antineoplastics	12 months
Chronic nonmalignant pain (CNMP)	NA	2 years
	Non-opioid analgesics	90 days

- Appropriate diagnoses – (may be subject to clinical review)
 - Cancer
 - Chronic Non-Malignant Pain (CNMP)
- Documented compliance on current therapy regimen (Subject to Clinical Consultant Review)
- Claims not exceeding quantity limitations established in Appendix A for adults and Appendix B for patients under age 18 years
- First claim for opioid product in past 90 days, is for ≤ 7 day supply, AND daily dose is ≤ 50 Morphine-Milligram-Equivalents (50 MME/day).
- Claim for opioid product is ≤ 90 Morphine-Milligram-Equivalents (90 MME/day)
- Agent must be appropriate for age

Denial Criteria

- Lack of appropriate diagnoses for therapy exceeding 60 days
- First claim for opioid product in the past 90 days and for > 7 days
- Daily dose for initial claim exceeds 50 Morphine-Milligram-Equivalents (50 MME/day)
- Daily dose after initial claim exceeds 90 Morphine-Milligram-Equivalents (90 MME/day)
- On Refill, must have exhausted 85% of previous day's supply
- Therapy will be denied if no approval criteria are met
- Patient with claim for Suboxone (brand or generic) or Subutex within the last 45 days

Required Documentation

Laboratory results:
MedWatch form:

Progress notes:

X
<input type="checkbox"/>

Disposition of Edit

- **Denial:** Edit 682 "Clinical Edit"

References

1. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep 2016;65 (March 15, 2016); (No. RR-1):1–49. DOI: <http://dx.doi.org/10.15585/mmwr.rr6501e1>
2. Chou R, Fanciullo GJ, Fine, PG, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. The Journal of Pain 2009; 10 (No. 2): 113-130: [http://www.jpain.org/article/S1526-5900\(08\)00831-6/pdf](http://www.jpain.org/article/S1526-5900(08)00831-6/pdf)
3. Oregon Health Authority – Opioid Conversion Calculator. <https://www.oregonpainguidance.org/opioidmedcalculator/> . Website accessed February 24, 2018.
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2018.
5. USPDI, Micromedex Online; 2018.
6. Drug Facts and Comparisons Online; 2017 by Clinical Drug Information. Opioid Analgesic Combinations; last accessed February 24, 2018.

Appendix A

Adult Dosing Chart

Short Acting Opioid Drugs	Max # of Units per Day
Codeine Sulfate 15 mg Oral tablet (360 mg)	24 tablets
Codeine Sulfate 15 mg / 2.5 mL Solution (360 mg)	60 mL
Codeine Sulfate 30 mg Oral tablet (360 mg)	12 tablets
Codeine Sulfate 30 mg / 5 mL Solution (360 mg)	60 mL
Codeine Sulfate 30 mg / 5 mL Solution (360 mg)	60 mL
Codeine Sulfate 60 mg Oral tablet (360 mg)	6 tablets
Hydromorphone 1 mg/ml Ampule (22 mg)	22 ml
Hydromorphone 2 mg/ml Ampule (22 mg)	11 ml
Hydromorphone 4 mg/ml Ampule (22 mg)	5.5 ml
Hydromorphone Hydrochloride 1 mg/mL Solution (22 mg)	22 mL
Hydromorphone Hydrochloride 2 mg Tablet (22 mg)	11 tablets
Hydromorphone Hydrochloride 4 mg Tablet (22 mg)	5.5 tablets
Hydromorphone Hydrochloride 8 mg Tablet (22 mg)	2.5 tablets
Hydromorphone Hydrochloride 3 mg Rectal Suppository	4 suppositories
Levorphanol 2 mg Tablet (24 mg)	12 tablets
Meperidine Hydrochloride 50 mg/5 mL Oral solution	60 mL
Meperidine Hydrochloride 50 mg Oral tablet (600 mg)	12 tablets
Meperidine Hydrochloride 100 mg Oral tablet (600 mg)	6 tablets
Methadone Hydrochloride 5 mg/5 mL Solution (120 mg)	120 mL
Methadone Hydrochloride 10 mg/5 mL Solution (120 mg)	60 mL
Methadone Hydrochloride 10 mg/mL Concentrated Solution (120 mg)	12 mL
Methadone Hydrochloride 5 mg Tablet (120 mg)	24 tablets
Methadone Hydrochloride 10 mg Tablet (120 mg)	12 tablets
Methadone Hydrochloride 40 mg Orally Disintegrating Tablet (120 mg)	3 tablets
Morphine Sulfate 10 mg/5 mL Solution (90 mg)	45 ml
Morphine Sulfate 20 mg/5 mL Solution (90 mg)	22.5 mL
Morphine Sulfate 100 mg/5 mL Solution (90 mg)	4.5 mL
Morphine Sulfate 15 mg Immediate-Release Tablet (90 mg)	6 tablets
Morphine Sulfate 30 mg Immediate-Release Tablet (90 mg)	3 tablets
Morphine Sulfate 5 mg Rectal Suppository (30 mg)	6 suppositories
Morphine Sulfate 10 mg Rectal Suppository (90 mg)	6 suppositories
Morphine Sulfate 20 mg Rectal Suppository (90 mg)	4 suppositories
Morphine Sulfate 30 mg Rectal Suppository (90 mg)	3 suppositories
Oxycodone Hydrochloride 5 mg/5 mL Oral solution (60 mg)	60 mL
Oxycodone Hydrochloride 20 mg/mL Oral solution (60 mg)	3 mL
Oxycodone Hydrochloride 5 mg Oral capsule (60 mg)	12 Capsules
Oxycodone Hydrochloride 5 mg Oral tablet (60 mg)	12 tablets

Short Acting Opioid Drugs	Max # of Units per Day
Oxycodone Hydrochloride 5 mg Oral tablet (60 mg)	12 tablets
Oxycodone Hydrochloride 7.5 mg Oral tablet (60 mg)	8 tablets
Oxycodone Hydrochloride 10 mg Oral tablet (60 mg)	6 tablets
Oxycodone Hydrochloride 15 mg Oral tablet (60 mg)	4 tablets
Oxycodone Hydrochloride 20 mg Oral tablet (60 mg)	3 tablets
Oxycodone Hydrochloride 30 mg Oral tablet (60 mg)	2 tablets
Oxymorphone Hydrochloride 5 mg Oral tablet (30 mg)	6 tablets
Oxymorphone Hydrochloride 10 mg Oral tablet (30 mg)	3 tablets
OPIOID AGONIST-ANTAGONIST ANALGESICS	
Butorphanol Tartrate 10 mg/mL Nasal Spray	0.5 mL

*Buprenorphine Hydrochloride Sublingual tablets are not included in this edit because they are included in the **Opiate-Dependence Step Therapy Edit**.

Appendix B

Pediatric Dosing Chart

Short Acting Opioid Drugs	Children max daily dose
Codeine Sulfate 15 mg Oral tablet	24 tablets
Codeine Sulfate 15 mg / 2.5 mL Solution (360 mg)	60 ml
Codeine Sulfate 30 mg Oral tablet	12 tablets
Codeine Sulfate 30 mg/5 mL solution	60 ml
Codeine Sulfate 30 mg/5 mL solution	60 mL
Codeine Sulfate 60 mg Oral tablet	6 tablets
Hydromorphone 1 mg/ml Ampule	12 ml
Hydromorphone 2 mg/ml Ampule	6 ml
Hydromorphone 4 mg/ml Ampule	3 ml
Hydromorphone Hydrochloride 1 mg/mL Solution	12 ml
Hydromorphone Hydrochloride 2 mg Tablet	6 tablets
Morphine Sulfate 10 mg/5 mL Solution	30 ml
Morphine Sulfate 20 mg/5 mL Solution	15 ml
Morphine Sulfate 100 mg/5 mL Solution	4 ml
Morphine Sulfate 15 mg Immediate-Release Tablet	2 tablets
Morphine Sulfate 5 mg Rectal Suppository	6 suppositories
Morphine Sulfate 10 mg Rectal Suppository	6 suppositories
Oxycodone Hydrochloride 5 mg/5 mL Oral solution	30 ml
Oxycodone Hydrochloride 20 mg/mL Oral solution	1.5 ml
Oxycodone Hydrochloride 5 mg Oral capsule	6 capsules
Oxycodone Hydrochloride 5 mg Oral tablet	6 tablets
Oxycodone Hydrochloride 5 mg Oral tablet	6 tablets

Short Acting Opioid Drugs	Children max daily dose
Oxycodone Hydrochloride 7.5 mg Oral tablet	4 tablets
Oxycodone Hydrochloride 10 mg Oral tablet	3 tablets
Oxycodone Hydrochloride 15 mg Oral tablet	2 tablets